S
Steve Dahlberg
Researcher at Fred Hutchinson Cancer Research Center
Publications - 10
Citations - 7761
Steve Dahlberg is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Non-Hodgkin's lymphoma & CHOP. The author has an hindex of 7, co-authored 10 publications receiving 7487 citations.
Papers
More filters
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Journal ArticleDOI
Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma
Richard I. Fisher,Ellen R. Gaynor,Steve Dahlberg,Martin M. Oken,Thomas M. Grogan,Evonne M. Mize,John H. Glick,Charles A. Coltman,Thomas P. Miller +8 more
TL;DR: CHOP remains the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin's lymphoma.
Journal ArticleDOI
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
Thomas P. Miller,Steve Dahlberg,J. Robert Cassady,David J. Adelstein,Catherine M. Spier,Thomas M. Grogan,Michael LeBlanc,Susan Carlin,Ellen M. Chase,Richard I. Fisher +9 more
TL;DR: Three cycles of CHOP followed by involved-field radiotherapy are superior to eight cycles ofCHOP alone for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma.
Journal ArticleDOI
Planned versus attained design in phase II clinical trials.
Stephanie Green,Steve Dahlberg +1 more
TL;DR: This work investigates several approaches to adapting stopping rules when the attained sample size is not the planned size and finds that a simple approach of testing HA: p = pA at the 0.02 level at the first stage works well across a variety of powers, pOs and pAs.
Journal ArticleDOI
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Carol J. Fabian,Roy Molina,Milan Slavik,Milan Slavik,Steve Dahlberg,Shankar Giri,Ronald L. Stephens +6 more
TL;DR: Considering the high incidence of PPE and response in previously untreated colon cancer patients who receive protracted continuous 5-FU, prophylactic pyridoxine in conjunction with this treatment modality might be useful.